Bernd R. Seizinger
Bernd R. Seizinger's purchase track record
How the stock did after each of Bernd R. Seizinger's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/11/2026 | ONCY | $83K | +2.4% | -4.8% | +11.6% |
| 1/16/2026 | ONCY | $104K | +10.9% | -15.8% | +7.5% |
| 10/11/2024 | APRE | $27K | +40.6% | -40.4% | -7.8% |
| 3/13/2024 | APRE | $50K | -22.2% | -42.0% | +7.5% |
| 6/6/2023 | APRE | $37K | +3.2% | -1.3% | +6.6% |
| 5/18/2022 | APRE | $36K | +37.8% | -36.8% | +0.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Oncolytics Biotech Activates All REO 033 Trial Facilities. Oncolytics Biotech has activated all planned facilities for Part A of its REO 033 trial in colorectal cancer. The company reported accelerating enrollment, with multiple participants admitted to the study. This progress occurs as the broader KRAS inhibitor market is projected to grow significantly in the coming years.
Transaction History
| APRE | ▲ Buy | Grant | 3,135 | $0 | 6/16/2026 | View on chart |
| ONCY | ▲ Buy | Open Market | 40,000 | $34K | 2/12/2026 | View on chart |
| ONCY | ▲ Buy | Open Market | 60,000 | $50K | 2/11/2026 | View on chart |
| ONCY | ▲ Buy | Open Market | 100,000 | $104K | 1/16/2026 | View on chart |
| APRE | ▲ Buy | Grant | 1,045 | $0 | 6/5/2025 | View on chart |
| APRE | ▲ Buy | Open Market | 10,000 | $27K | 10/11/2024 | View on chart |
| APRE | ▲ Buy | Grant | 1,045 | $0 | 6/20/2024 | View on chart |
| APRE | ▲ Buy | Open Market | 6,860 | $50K | 3/13/2024 | View on chart |
| APRE | ▲ Buy | Grant | 500 | $0 | 8/23/2023 | View on chart |
| APRE | ▲ Buy | Open Market | 6,029 | $22K | 6/7/2023 | View on chart |
| APRE | ▲ Buy | Open Market | 4,068 | $15K | 6/6/2023 | View on chart |
| APRE | ▲ Buy | Grant | 5,995 | $0 | 7/28/2022 | View on chart |
| APRE | ▲ Buy | Open Market | 50,000 | $36K | 5/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Aprea Therapeutics Announces October Conference Presentations
Aprea Therapeutics will present at several conferences in October. The company’s appearance is intended to share progress on its research and development efforts. The presentation may offer new information to investors and analysts about the company’s pipeline and strategy. The event is a routine update for the company’s stakeholders.
Aprea Therapeutics Announces October Conference Presentations. Aprea Therapeutics will present at several conferences in October. The company’s appearance is intended to share progress on its research and development efforts. The presentation may offer new information to investors and analysts about the company’s pipeline and strategy. The event is a routine update for the company’s stakeholders.